RT Journal Article
SR Electronic
A1 Jacobson, Anne
T1 Rosuvastatin Offers No Significant Benefit for Older Patients with Heart Failure
JF MD Conference Express
YR 2007
FD SAGE Publications
VO 7
IS 7
SP 13
OP 14
DO 10.1177/155989770700700706
UL http://mdc.sagepub.com/content/7/7/13.abstract
AB Rosuvastatin was found to have no significant benefit in the prevention of cardiovascular death, myocardial infarction, or stroke in symptomatic older patients with systolic heart failure of ischemic etiology in the Controlled Rosuvastatin Multinational [CORONA] trial. However, statin therapy was associated with significantly fewer hospitalizations and significantly decreased levels of low-density lipoprotein compared with placebo.